Association Between Autoantibody Phenotype and Cutaneous Adverse Reactions to Hydroxychloroquine in Dermatomyositis

JAMA Dermatology
Paige W WolstencroftDavid F Fiorentino

Abstract

Hydroxychloroquine sulfate is a commonly used medication for patients with dermatomyositis and has been associated with a uniquely elevated risk of adverse cutaneous reactions in this population. No studies to date have examined whether certain subsets of patients with dermatomyositis are at increased risk of experiencing a hydroxychloroquine-associated skin eruption. To identify disease features that increase the risk of hydroxychloroquine-associated skin eruption in adults with dermatomyositis. A retrospective cohort study was conducted in the outpatient dermatology clinic at a tertiary academic referral center. All adults with dermatomyositis (age >18 years) who started receiving hydroxychloroquine between July 1, 1990, and September 13, 2016, were eligible for the analysis. Patients were considered to have a hydroxychloroquine-associated skin eruption if a skin eruption had developed within their first 4 weeks of treatment and resolved with discontinuation of hydroxychloroquine therapy. One or more doses of hydroxychloroquine. The associations between autoantibodies (against transcription intermediary factor 1γ [TIF-1γ], nucleosome-remodeling deacetylase complex [Mi-2], nuclear matrix protein [NXP-2], small ubiquitinlike mo...Continue Reading

References

Feb 20, 1975·The New England Journal of Medicine·A Bohan, J B Peter
Feb 13, 1975·The New England Journal of Medicine·A Bohan, J B Peter
Apr 1, 1984·Journal of the American Academy of Dermatology·T Y WooC Hawkins
Jul 20, 2005·Archives of Dermatology·Gina Charlene Ang, Victoria P Werth
Mar 15, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Alenka KuznikRoman Jerala
Mar 31, 2015·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jie AnKeith B Elkon
Nov 5, 2016·Annual Review of Medicine·Jie AnKeith B Elkon
Nov 9, 2017·JAMA Dermatology·Paige W WolstencroftDavid F Fiorentino

❮ Previous
Next ❯

Citations

Feb 26, 2020·American Journal of Clinical Dermatology·Gabriela A CobosRuth Ann Vleugels
Jul 18, 2020·Journal of the European Academy of Dermatology and Venereology : JEADV·S Chavez-AlvarezJ Ocampo-Candiani
Jan 31, 2021·Joint, Bone, Spine : Revue Du Rhumatisme·Alina DimaLaurent Arnaud
Feb 20, 2021·Journal of the American Academy of Dermatology·Andressa L Akabane, Gideon P Smith
Mar 29, 2021·ACR Open Rheumatology·Jemima AlbaydaLisa Christopher-Stine
Apr 13, 2021·Arthritis & Rheumatology·Ingrid E Lundberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.